Log in to save to my catalogue

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment o...

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment o...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6942573

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

About this item

Full title

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Publisher

Tokyo: Springer Japan

Journal title

Journal of gastroenterology, 2020-01, Vol.55 (1), p.113-122

Language

English

Formats

Publication information

Publisher

Tokyo: Springer Japan

More information

Scope and Contents

Contents

Background
A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC). LEN had an effect on overall survival (OS) compared to SOR, statistically confirmed by non-inferiority [OS: median = 13.6 months v...

Alternative Titles

Full title

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6942573

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6942573

Other Identifiers

ISSN

0944-1174

E-ISSN

1435-5922

DOI

10.1007/s00535-019-01642-1

How to access this item